{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T20:09:32Z","timestamp":1712088572208},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T00:00:00Z","timestamp":1404345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The basis of response of chronic hepatitis C (<jats:styled-content style=\"fixed-case\">CHC<\/jats:styled-content>) patients to treatment is still unclear, and there may be many other factors which influence treatment outcome other than the existing ones. The serum concentration of C3 closely reflects the total complement activity, and individuals affected by C3 deficiency suffer from recurrent pyogenic infections. This study aims to find out relationship between levels of C3 in serum and its functional <jats:styled-content style=\"fixed-case\">SNP<\/jats:styled-content>s with response to treatment. The study included 132 <jats:styled-content style=\"fixed-case\">CHC<\/jats:styled-content> patients of which 48 received Pegylated <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>+Ribavirin and 81 controls. C3 levels and its three known functional <jats:styled-content style=\"fixed-case\">SNP<\/jats:styled-content>'s genotyped by <jats:styled-content style=\"fixed-case\">ELISA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">SSP PCR<\/jats:styled-content>, respectively. C3 Level of the healthy group was significantly higher (88.5\u00a0\u00b1\u00a019\u00a0mg\/dL) when compared to <jats:styled-content style=\"fixed-case\">CHC<\/jats:styled-content> group (56\u00a0\u00b1\u00a018\u00a0mg\/dL; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Thirty\u2010three of 36 responders were rs2230201 <jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content> genotype carriers, whereas 9 of 12 nonresponders were non\u2010<jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content> genotype. The \u2018C\u2019 allele of rs2230201 was found to be associated with increased serum C3 levels when compared to other genotypes in healthy group, whereas <jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> genotype was associated with lowered serum C3 in <jats:styled-content style=\"fixed-case\">CHC<\/jats:styled-content> group. A serum C3 value of &lt;53\u00a0mg\/dL was predictive of <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> with sensitivity 63.89% and specificity 66.67%. The study supports the observation that rs2230201 \u2018C\u2019 allele is associated with increase of serum C3 levels when compared to \u2018T\u2019 allele which may confer advantage in attaining <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> when present in homozygous condition. The study suggests that patients with serum C3 value &lt;53\u00a0mg\/dL and non\u2010<jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content> genotypes may not respond to treatment.<\/jats:p>","DOI":"10.1111\/jvh.12280","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T10:36:53Z","timestamp":1404383813000},"page":"184-191","source":"Crossref","is-referenced-by-count":5,"title":["rs2230201 polymorphism may dictate complement C3 levels and response to treatment in chronic hepatitis C patients"],"prefix":"10.1111","volume":"22","author":[{"given":"S. J.","family":"Chowdhury","sequence":"first","affiliation":[{"name":"Department of Medicine Maulana Azad Medical College Delhi University New Delhi India"},{"name":"Department of Biotechnology Gauhati University Guwahati India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. K.","family":"Karra","sequence":"additional","affiliation":[{"name":"Department of Medicine Maulana Azad Medical College Delhi University New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. K.","family":"Gumma","sequence":"additional","affiliation":[{"name":"Department of Medicine Maulana Azad Medical College Delhi University New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bharali","sequence":"additional","affiliation":[{"name":"Department of Biotechnology Gauhati University Guwahati India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Kar","sequence":"additional","affiliation":[{"name":"Department of Medicine Maulana Azad Medical College Delhi University New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21347"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1113"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1923"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.22.12708"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(76)90060-X"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108263"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1542\/peds.71.1.81","article-title":"Inherited deficiency of the third component of complement associated with recurrent pyogenic infections, circulating immune complexes, and vasculitis in a Dutch family","volume":"71","author":"Roord JJ","year":"1983","journal-title":"Pediatrics"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.16.5021"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60042-5"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01893021"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030374"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem321"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072618"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_7_16_1","first-page":"165","article-title":"Hepatitis C Protocols","volume":"19","author":"Chayama K","year":"1998","journal-title":"Methods Mol Med"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002916"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-10-S3-S4"},{"key":"e_1_2_7_19_1","unstructured":"DeanAG SullivanKM SoeM.OpenEpi: Open Source Epidemiological Statistics for Public Health Version 2.3.1."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2006.08.003"},{"key":"e_1_2_7_22_1","first-page":"1","article-title":"NIH consensus statement on management of hepatitis C","volume":"19","author":"National Institute of Health U.S.A","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.4.450"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2008.03.003"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100010"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1573"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06577-11"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01729.x"},{"key":"e_1_2_7_29_1","first-page":"509","article-title":"Circulating conversion products of c3 in liver disease","volume":"14","author":"Teisberg P","year":"1973","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.1.362"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genom.7.080505.115630"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp215"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/18.5.769"},{"key":"e_1_2_7_34_1","unstructured":"JulesL.Optimal pre\u2010treatment HCV RNA level for prediction of SVR with peginterferon alfa\u20102a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in genotype 1 patients: Generalised Additive logistic regression Model (GAM) analysis. EASL April 2007 Barcelona Spain."}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12280","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12280","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:01:08Z","timestamp":1696287668000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/jvh.12280"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12280","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,3]]}}}